Overview

A Study of MKC-442 in Combination With Other Anti-HIV Drugs

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to see if it is safe and effective to give MKC-442 plus stavudine (d4T) plus didanosine (ddI) plus hydroxyurea.
Phase:
Phase 2
Details
Lead Sponsor:
Triangle Pharmaceuticals
Treatments:
Didanosine
Emivirine
Hydroxyurea
Reverse Transcriptase Inhibitors
Stavudine